173 related articles for article (PubMed ID: 33837964)
21. T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
Gutierrez M; Bladek P; Goksu B; Murga-Zamalloa C; Bixby D; Wilcox R
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569479
[TBL] [Abstract][Full Text] [Related]
22. Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.
Rose A; Zhang L; Jain AG; Poovathukaran Babu A; Sokol L; Saeed H; Mo Q; Fan W; Zhang X
Am J Hematol; 2023 Jun; 98(6):913-921. PubMed ID: 36964941
[TBL] [Abstract][Full Text] [Related]
23. T-cell prolymphocytic leukemia: A rare disease in an elderly female.
Madaris L
J Am Acad Nurse Pract; 2010 Dec; 22(12):648-53. PubMed ID: 21129072
[TBL] [Abstract][Full Text] [Related]
24. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
[TBL] [Abstract][Full Text] [Related]
25. False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab: Potential Pitfalls for the Misdiagnosis of B-Cell Neoplasms.
Chen PP; Tormey CA; Eisenbarth SC; Torres R; Richardson SS; Rinder HM; Smith BR; Siddon AJ
Am J Clin Pathol; 2019 Jan; 151(2):154-163. PubMed ID: 30307483
[TBL] [Abstract][Full Text] [Related]
26. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
[TBL] [Abstract][Full Text] [Related]
27. Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia.
Alsawah F; Benitez L; Choi S; Marini B; Perissinotti A; Skyles A; Burke P; Pettit K; Crouch A; Fox H; Bixby D
Blood Adv; 2019 Nov; 3(21):3333-3336. PubMed ID: 31698446
[TBL] [Abstract][Full Text] [Related]
28. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
[TBL] [Abstract][Full Text] [Related]
29. T-cell chronic lymphocytic leukemia/T-prolymphocytic leukemia: Experience with single agent bendamustine.
Thota NK; Sadashivudu G; Gandhi LV; Pragnya C; Roshni TP; Raghunadharao D
Indian J Cancer; 2015; 52(2):193-4. PubMed ID: 26853400
[No Abstract] [Full Text] [Related]
30. From the archives of MD Anderson Cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature.
Nahmod KA; Thakral B; Aakash FNU; Iyer SP; Medeiros LJ; Quesada AE
Ann Diagn Pathol; 2023 Feb; 62():152077. PubMed ID: 36549077
[TBL] [Abstract][Full Text] [Related]
31. [Successful treatment of T-cell prolymphocytic leukemia (T-PLL) with fludarabine monophosphate].
Maeda A; Iwai K; Ishibashi T
Rinsho Ketsueki; 2009 Aug; 50(8):658-62. PubMed ID: 19915381
[TBL] [Abstract][Full Text] [Related]
32. T-cell prolymphocytic leukemia (T-PLL) with overlapping cytomorphological features with T-CLL and T-ALL: a case initially diagnosed by fine-needle aspiration cytology and immunocytochemistry.
Das DK; Pathan SK; Joneja M; Al-Musawi FA; John B; Mirza KR
Diagn Cytopathol; 2013 Apr; 41(4):360-5. PubMed ID: 21987484
[TBL] [Abstract][Full Text] [Related]
33. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Boidol B; Kornauth C; van der Kouwe E; Prutsch N; Kazianka L; Gültekin S; Hoermann G; Mayerhoefer ME; Hopfinger G; Hauswirth A; Panny M; Aretin MB; Hilgarth B; Sperr WR; Valent P; Simonitsch-Klupp I; Moriggl R; Merkel O; Kenner L; Jäger U; Kubicek S; Staber PB
Blood; 2017 Dec; 130(23):2499-2503. PubMed ID: 28972014
[TBL] [Abstract][Full Text] [Related]
34. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
[TBL] [Abstract][Full Text] [Related]
35. T-cell prolymphocytic leukemia frequently shows cutaneous involvement and is associated with gains of MYC, loss of ATM, and TCL1A rearrangement.
Hsi AC; Robirds DH; Luo J; Kreisel FH; Frater JL; Nguyen TT
Am J Surg Pathol; 2014 Nov; 38(11):1468-83. PubMed ID: 25310835
[TBL] [Abstract][Full Text] [Related]
36. T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis.
Yoshioka Y; Nagao M; Saitoh T; Yoshioka S; Tsunemine H; Itoh K; Kodaka T; Takahashi T
J Clin Exp Hematop; 2015; 55(1):17-21. PubMed ID: 26106002
[TBL] [Abstract][Full Text] [Related]
37. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene.
Sun S; Fang W
Biomed Pharmacother; 2020 Jun; 126():110107. PubMed ID: 32247279
[TBL] [Abstract][Full Text] [Related]
38. Broken heart by T-prolymphocytic leukemia.
Arranto C; Tzankov A
Blood; 2017 Aug; 130(5):691. PubMed ID: 28775161
[No Abstract] [Full Text] [Related]
39. T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).
Cao TM; Coutre SE
Hematology; 2003 Feb; 8(1):1-6. PubMed ID: 12623420
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr virus-positive diffuse large B-cell lymphoma after sustained remission of T-cell prolymphocytic leukemia with alemtuzumab.
Ichikawa S; Fukuhara N; Saito K; Yokoyama H; Onodera K; Onishi Y; Ichinohasama R; Harigae H
Leuk Lymphoma; 2020 Jun; 61(6):1504-1507. PubMed ID: 31960738
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
